Stock CNTB CONNECT BIOPHARMA HOLDINGS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Connect Biopharma Holdings Limited

Equities

CNTB

US2075231017

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
1.79 USD +14.38% Intraday chart for Connect Biopharma Holdings Limited +1.70% +51.69%
Apr. 17 Sector Update: Health Care Stocks Retreating Late Afternoon MT
Apr. 17 Sector Update: Health Care MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma
GL
Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma
AQ
Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma
GL
Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management
NE
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
GL
Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference
GL
Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors
GL
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
GL
Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023
GL
Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management
NE
Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China
GL
Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China
AQ
Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis
GL
Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023
GL
Connect Biopharma : INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K - Form 6-K
PU
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
GL
Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
GL
Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
AQ
Connect Biopharma to Participate in Upcoming September Investor Conferences
GL
Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CNTB Stock
  4. News Connect Biopharma Holdings Limited
  5. Press Releases